156 related articles for article (PubMed ID: 28102776)
21. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts.
Mousa SA; Yalcin M; Bharali DJ; Meng R; Tang HY; Lin HY; Davis FB; Davis PJ
Lung Cancer; 2012 Apr; 76(1):39-45. PubMed ID: 22024450
[TBL] [Abstract][Full Text] [Related]
22. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
23. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
[TBL] [Abstract][Full Text] [Related]
24. Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies.
Shi S; Zhou M; Li X; Hu M; Li C; Li M; Sheng F; Li Z; Wu G; Luo M; Cui H; Li Z; Fu R; Xiang M; Xu J; Zhang Q; Lu L
J Control Release; 2016 Aug; 235():1-13. PubMed ID: 27235150
[TBL] [Abstract][Full Text] [Related]
25. Tetrac-decorated chitosan-coated PLGA nanoparticles as a new platform for targeted delivery of SN38.
Alibolandi M; Amel Farzad S; Mohammadi M; Abnous K; Taghdisi SM; Kalalinia F; Ramezani M
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1003-1014. PubMed ID: 29806500
[TBL] [Abstract][Full Text] [Related]
26. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
27. Biodegradable polymeric system for cisplatin delivery: development, in vitro characterization and investigation of toxicity profile.
Alam N; Khare V; Dubey R; Saneja A; Kushwaha M; Singh G; Sharma N; Chandan B; Gupta PN
Mater Sci Eng C Mater Biol Appl; 2014 May; 38():85-93. PubMed ID: 24656356
[TBL] [Abstract][Full Text] [Related]
28. Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules.
Amoozgar Z; Goldberg MS
Nanomedicine (Lond); 2017 Apr; 12(7):729-743. PubMed ID: 28322107
[TBL] [Abstract][Full Text] [Related]
29. Construction and comparison of different nanocarriers for co-delivery of cisplatin and curcumin: A synergistic combination nanotherapy for cervical cancer.
Li C; Ge X; Wang L
Biomed Pharmacother; 2017 Feb; 86():628-636. PubMed ID: 28027539
[TBL] [Abstract][Full Text] [Related]
30. Tetrac-conjugated polymersomes for integrin-targeted delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
Alibolandi M; Rezvani R; Farzad SA; Taghdisi SM; Abnous K; Ramezani M
Int J Pharm; 2017 Oct; 532(1):581-594. PubMed ID: 28935257
[TBL] [Abstract][Full Text] [Related]
31. A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy.
Wang ZQ; Liu K; Huo ZJ; Li XC; Wang M; Liu P; Pang B; Wang SJ
J Nanobiotechnology; 2015 Oct; 13():63. PubMed ID: 26427800
[TBL] [Abstract][Full Text] [Related]
32. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain.
Gdowski AS; Ranjan A; Sarker MR; Vishwanatha JK
Nanomedicine (Lond); 2017 Sep; 12(17):2083-2095. PubMed ID: 28805551
[TBL] [Abstract][Full Text] [Related]
33. Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin.
Pradhan R; Ramasamy T; Choi JY; Kim JH; Poudel BK; Tak JW; Nukolova N; Choi HG; Yong CS; Kim JO
Carbohydr Polym; 2015 Jun; 123():313-23. PubMed ID: 25843864
[TBL] [Abstract][Full Text] [Related]
34. Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3.
Schmohl KA; Müller AM; Wechselberger A; Rühland S; Salb N; Schwenk N; Heuer H; Carlsen J; Göke B; Nelson PJ; Spitzweg C
Endocr Relat Cancer; 2015 Dec; 22(6):941-52. PubMed ID: 26307023
[TBL] [Abstract][Full Text] [Related]
35. Tetraiodothyroacetic acid-conjugated polyethylenimine for integrin receptor mediated delivery of the plasmid encoding IL-12 gene.
Sheikhsaran F; Sadeghpour H; Khalvati B; Entezar-Almahdi E; Dehshahri A
Colloids Surf B Biointerfaces; 2017 Feb; 150():426-436. PubMed ID: 27847224
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system.
Lin HY; Landersdorfer CB; London D; Meng R; Lim CU; Lin C; Lin S; Tang HY; Brown D; Van Scoy B; Kulawy R; Queimado L; Drusano GL; Louie A; Davis FB; Mousa SA; Davis PJ
PLoS Comput Biol; 2011 Feb; 7(2):e1001073. PubMed ID: 21304935
[TBL] [Abstract][Full Text] [Related]
37. α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug.
Graf N; Bielenberg DR; Kolishetti N; Muus C; Banyard J; Farokhzad OC; Lippard SJ
ACS Nano; 2012 May; 6(5):4530-9. PubMed ID: 22584163
[TBL] [Abstract][Full Text] [Related]
38. NDAT suppresses pro-inflammatory gene expression to enhance resveratrol-induced anti-proliferation in oral cancer cells.
Ho Y; Wu CY; Chin YT; Li ZL; Pan YS; Huang TY; Su PY; Lee SY; Crawford DR; Su KW; Chiu HC; Shih YJ; Changou CA; Yang YSH; Whang-Peng J; Chen YR; Lin HY; Mousa SA; Davis PJ; Wang K
Food Chem Toxicol; 2020 Feb; 136():111092. PubMed ID: 31883986
[TBL] [Abstract][Full Text] [Related]
39. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
40. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation.
Guo S; Lin CM; Xu Z; Miao L; Wang Y; Huang L
ACS Nano; 2014 May; 8(5):4996-5009. PubMed ID: 24720540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
